The world has seen the rise of many innovative, creative and curious scientists who research various aspects of science and make huge contributions. According to Impact Journals, Mikhail Blagosklonny is one of them. His research interests include molecular and cellular biology, signal transduction, cell cycle, oncogenes and tumor suppressors and anti-cancer therapeutics.

He aims at understanding aging and cancer, two of the largest dilemmas in the world today. One of his main achievements is the development of a hypothesis about the possible role of Target Of Rapamycin (TOR) in the aging of humans and other organisms.

According to Mikhail Blagosklonny, TOR, being a nutrient sensing path, determines how an organism’s body coordinates growth and aging. He argues that aging results from cellular senescence.

It leads to overworking of the cells thus blocking the feedback pathways and further impairing their functioning. This leads to cell deterioration, aging and age-related diseases which may cause organ damage and even death due to lack of homeostasis.

Since TOR is triggered by nutrients, insulin and growth factors, it causes cell-hyper-function. As such, TOR presence is directly related to every age-related disease. From his findings, he proposed that a cancer drug called rapamycin may be a possible treatment for life extension.

Mikhail Blagosklonny currently works at the Roswell Park Cancer Institute in New York as a professor of Oncology.  At the facility, he facilitates the development of innovative cancer treatments, prevention methods and anti-cancer stratagem.

When he is not teaching at the institute, he is editing scholarly research articles. He is the Founding editor and Editor-in-chief of Cell Cycle and co-editor and Co-founder of Aging, Oncotarget and Oncoscience.

A master’s degree in internal medicine and PHD in experimental medicine and cardiology, both from the First Pavlov State Medical University of St. Peterburg, laid a great foundation for Mikhail’s career.

He began his teaching career at The New York Medical College in Valhalla in 2002 when he was appointed associate professor of medicine. He worked there until 2009.